360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

IsoRay Inc

Type: Company

Name: IsoRay Inc

First reported 9 hours ago - Updated 9 hours ago - 1 reports

Abbott Laboratories

CytRx Offers Initial Results from Aldoxorubicin Trial; Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced initial data from a Phase 1b clinical trial evaluating the pharmacokinetics and safety of aldoxorubicin, its novel conjugate of ... [Published BioMedReports - 9 hours ago]

Entities: Stent, CytRx Corporation, Abbott Laboratories

First reported 14 hours ago - Updated 14 hours ago - 1 reports

IsoRay names distributor for Greece

-- Medical isotope developer IsoRay has signed on IASIS Medical as a new distributor for the Greek market.IASIS will exclusively distribute IsoRay's complete product line in Greece, according to IsoRay.Copyright © 2013 AuntMinnieEurope.com ... [Published AuntMinnieEurope - 14 hours ago]

Entities: IsoRay Inc, Greece, Isotope

First reported 19 hours ago - Updated 19 hours ago - 1 reports

IsoRay Announces A New International Distributor For Greece

RICHLAND, Wash.IASIS Medical is ideally suited to support IsoRay's products, which utilize the uniqueness of IsoRay's Cs-131 isotope to attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gyn ... [Published Bio-Medicine - 19 hours ago]

Entities: IsoRay Inc, Greece, head and neck cancer, Cancer

First reported 19 hours ago - Updated 19 hours ago - 1 reports

IsoRay Announces A New International Distributor For Greece

IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology ... [Published Zecco - 19 hours ago]

Entities: IsoRay Inc, brachytherapy, Cancer

First reported 19 hours ago - Updated 19 hours ago - 1 reports

IsoRay Announces A New International Distributor For Greece

RICHLAND, Wash.IASIS Medical is ideally suited to support IsoRay's products, which utilize the uniqueness of IsoRay's$ Cs-131 isotope to attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gyn ... [Published ADVFN UK - 19 hours ago]

Entities: IsoRay Inc, brachytherapy, Greece, Cancer, Richland (Washington, United States)

First reported May 15 2013 - Updated May 15 2013 - 1 reports

IsoRay (ISR): FQ3 EPS of -$0.02 beats by $0.01. Revenue of $1.25M beats by $0.13M. (PR)

:35 AM ET IsoRay (ISR): FQ3 EPS of -$0.02 beats by $0.01. Revenue of $1.25M beats by $0.13M. (PR) ... [Published Seeking Alpha - May 15 2013]

Entities: IsoRay Inc

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

IsoRay on Display at the American Brachytherapy Society (ABS) Convention Featuring Its Cesium-131 Cancer Fighting Portfolio

5 Year Data to Be Presented by UPMC Shows IsoRay's Cesium-131 Achieved Outstanding Biochemical (PSA) Control and a Just Completed York Hospital Study Will Report Cesium-131 Returns Patients to Base Line Faster Than Iodine-125RICHLAND, WA--(Marketwired ... [Published BioMedReports - Apr 19 2013]

Entities: IsoRay Inc, brachytherapy, Cancer

First reported Apr 15 2013 - Updated Apr 15 2013 - 3 reports

IsoRay on Display at the American Brachytherapy Society (ABS. . .

IsoRay on Display at the American Brachytherapy Society (ABS) Convention Featuring Its Cesium-131 Cancer Fighting Portfolio5 Year Data to Be Presented by UPMC Shows IsoRay's Cesium-131 Achieved Outstanding Biochemical (PSA) Control and a Just Completed ... [Published Equities.com - Apr 15 2013]

Entities: IsoRay Inc, brachytherapy, Cancer, Radiation Therapy, Richland (Washington, United States)

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Immunotech Laboraties Appoints New VP of Business Development

Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) announces the company has appointed Blaine Nabors as VP of Business Development.Immunotech President & Founder Harry Zhabilov today announced the appointment of Blaine Nabors as Immunotech's VP of Business ... [Published NewsBlaze - Apr 15 2013]

Entities: Business Development, Dundee Corporation, Dream International Ltd, Appointed, Immunotech Laboratories Inc

First reported Feb 05 2013 - Updated Feb 06 2013 - 1 reports

Metastatic Brain Cancer Video Released by Cornell Weill

RICHLAND, Wash., Feb. 5, 2013 /PRNewswire/ -- IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their ... [Published Business Technology - Feb 05 2013]

Entities: Brain Cancer, Metastatic, IsoRay Inc, Radioisotope

First reported Feb 05 2013 - Updated Feb 05 2013 - 1 reports

Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay

By BuySellShort : There has been much interest in cancer stocks of late, especially those in the radiation field. Spectrum Pharmaceuticals Inc. ( SPPI ) has been subject to buyout rumors and Delcath Systems Inc. ( DCTH ) has seen it shares gain ahead ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 05 2013]

Entities: IsoRay Inc, Radiation, Spectrum

Quotes

...XIENCE Xpedition 48 may provide important cost savings to the system," said Peter Smits, M D , Maasstad Ziekenhuis, Rotterdam, the Netherlands. "I believe that this new treatment option, backed by the robust clinical outcomes of the XIENCE family of drug eluting stents, will help physicians in the treatment of long lesions."

CytRx Offers Initial Results from Aldoxorubicin Trial; Abbott Announces CE Mark for World's Longe ... [Published BioMedReports - 9 hours ago]

IsoRay Chairman and CEO Dwight Babcock commented, "We are very optimistic about the growth in adoption of our growing array of new products and look to the international market to contribute in the future as IsoRay's products receive foreign regulatory approvals and licenses needed for the sale of our products in additional countries. All of our products currently carry the CE Mark, making them eligible to be sold in 31 European nations. Physicians and institutions throughout the US are continuing to report outstanding results in the use of our Cs-131 seeds for brain cancer, head and neck cancer, prostate cancer and lung cancers. Given this growing acceptance and interest, we remain committed to our strategic national and international marketing objectives and believe this will contribute to our long term success."

IsoRay Announces A New International Distributor For Greece [Published Zecco - 19 hours ago]

IsoRay CEO Dwight Babcock commented, "IsoRay is pleased to once again participate at the ABS annual meeting. At this venue, thought leaders and institutions, including Drs. Ron Benoit, Sushil Beriwal and Ryan P Smith of the University of Pittsburg Medical Center (UPMC), UMPC Video and Drs. Amit A Shaw and Gregory A Fortier of the York Cancer Center, will present their papers documenting their experiences and success in using our products. In all there are 5 papers being presented during the convention. All of the studies being presented at the annual meeting will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used. With the continued publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer patients."

IsoRay on Display at the American Brachytherapy Society (ABS) Convention Featuring Its Cesium-131 ... [Published BioMedReports - Apr 19 2013]

"We are pleased that the DSMB has recommended that GTx continue as planned with our clinical studies of enobosarm under the existing protocols,” said Mitchell S Steiner, MD, Chief Executive Officer of GTx. “The extensive safety database GTx is compiling from the numerous clinical studies of enobosarm will be a critical component of GTx's application for marketing approval, which we hope to submit following receipt of topline data from our Phase III clinical trials in the 3rd quarter of 2013."

GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned; Luminex Receives ... [Published BioMedReports - Apr 16 2013]

More Content

sort by: Date \| Relevance
CytRx Offers Initial Results from Aldoxorubicin... [Published BioMedReports - 9 hours ago]
IsoRay names distributor for Greece [Published AuntMinnieEurope - 14 hours ago]
IsoRay Announces A New International Distributo... [Published Bio-Medicine - 19 hours ago]
IsoRay Announces A New International Distributo... [Published Zecco - 19 hours ago]
IsoRay Announces A New International Distributo... [Published ADVFN UK - 19 hours ago]
IsoRay Announces A New International Distributo... [Published Financial Services - 19 hours ago]
IsoRay, Inc. (ISR) - Medical Equipment - Deals ... [Published TransWorldNews - May 19 2013]
Gilead Offers Response Data from Idelalisib; Sa... [Published BioMedReports - May 16 2013]
IsoRay (ISR): FQ3 EPS of -$0.02 beats by $0.01.... [Published Seeking Alpha - May 15 2013]
IsoRay, Inc. Reports Third Quarter Results [Published Marketwire - Breaking News Releases - May 15 2013]
IsoRay on Display at the American Brachytherapy... [Published BioMedReports - Apr 19 2013]
A Look At The Prostrate Cancer Treatment Market [Published Seeking Alpha - Apr 17 2013]
GTx's Phase III Clinical Studies of Enobosarm (... [Published BioMedReports - Apr 16 2013]
IsoRay on Display at the American Brachytherapy... [Published Equities.com - Apr 15 2013]
IsoRay on Display at the American Brachytherapy... [Published Interest!ALERT - Apr 15 2013]
Immunotech Laboraties Appoints New VP of Busine... [Published NewsBlaze - Apr 15 2013]
IsoRay on Display at the American Brachytherapy... [Published Market Wire - Apr 15 2013]
IsoRay, Inc. States Its Policy Not to Comment o... [Published PR Newswire: Financial Services - Feb 27 2013]
First International Brain Cancer Treatments Per... [Published Marketwire - Breaking News Releases - Feb 21 2013]
IsoRay, Inc. Reports Second Quarter Results [Published Marketwire - Breaking News Releases - Feb 14 2013]
Cancer Radiation Stocks To Consider: Delcath, S... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 05 2013]
Metastatic Brain Cancer Video Released by Corne... [Published Business Technology - Feb 05 2013]
New Evidence in IsoRay's Brain Cancer Treatment [Published Marketwire - Breaking News Releases - Dec 12 2012]
IsoRay's Cesium-131 Seeds Proves Successful for... [Published Marketwire - Breaking News Releases - Dec 11 2012]

Press Releases

sort by: Date \| Relevance
IsoRay Announces A New International Distributo... [Published Financial Services - 19 hours ago]
IsoRay, Inc. Reports Third Quarter Results [Published Marketwire - Breaking News Releases - May 15 2013]
IsoRay, Inc. States Its Policy Not to Comment o... [Published PR Newswire: Financial Services - Feb 27 2013]
First International Brain Cancer Treatments Per... [Published Marketwire - Breaking News Releases - Feb 21 2013]
IsoRay, Inc. Reports Second Quarter Results [Published Marketwire - Breaking News Releases - Feb 14 2013]